| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Hilleman Jeryl L serves as a Director at SIBN and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 1 buy and 8 sells. Those positions are worth an estimated $5K at current prices.
Historically, Hilleman Jeryl L's trades have earned a middling insider score of 61/100 across 6 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +18.1%.
The biggest single holding is NERV (~$5K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 1,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | NVCR Novocure Limited | Director | Sell | 2,945 | $15.77 | $46,444.71 | -17.5% | +11.6% | - | |
| Jun 3, 2025 | NVCR Novocure Ltd | Director | Sell | 999 | $17.26 | $17,246.54 | -15.2% | -28.5% | +0.0% | |
| Jun 20, 2023 | SIBN Si-Bone, Inc. | Director | Sell10b5-1 | 4,162 | $28.37 | $118,075.94 | -21.3% | -20.7% | -57.2% | |
| Jun 13, 2022 | SIBN Si-Bone, Inc. | Director | Sell | 1,924 | $13.81 | $26,561.97 | -23.3% | +31.4% | +101.8% | |
| Jun 10, 2022 | NVCR Novocure Ltd | Director | Sell | 407 | $69.61 | $28,331.27 | -13.8% | +25.0% | -38.4% | |
| Jun 25, 2021 | SIBN Si-Bone, Inc. | Director | Sell | 4,400 | $33.71 | $148,324.00 | -34.8% | -28.2% | -57.8% | |
| Dec 18, 2020 | NVCR Novocure Ltd | Director | Sell | 2,500 | $166.40 | $416,000.00 | -42.4% | - | - | |
| Jun 26, 2019 | NERV Minerva Neurosciences, Inc. | Director | Buy | 1,000 | $5.25 | $5,250.00 | New | - | - |